Charles River Laboratories (CRL) Plunges 28.27% Amid FDA Animal Testing Phase-Out
1min read Charles River Laboratories International (CRL) shares fell 0.20% today, marking the second consecutive day of decline, with a total drop of 28.27% over the past two days. The stock price hit its lowest level since May 2017, experiencing an intraday decline of 8.09%.
Charles River Laboratories International (CRL) has recently faced a significant challenge due to the FDA's decision to phase out animal testing. This regulatory change directly impacts the company's core business model, which has traditionally relied on animal testing services. The shift in regulatory policy has raised concerns among investors, leading to a negative market reaction and a substantial decline in the company's stock price. The news from April 10, 2025, underscores this development as a major factor influencing CRL's stock performance.
The FDA's decision to phase out animal testing is a pivotal moment for the biotechnology and pharmaceutical industries. This regulatory change aims to promote more ethical and humane testing methods, aligning with growing public and scientific consensus on the need for alternatives to animal testing. However, for companies like Charles River Laboratories, which have built their business models around animal testing services, this shift poses a significant threat. The company will need to adapt quickly to new regulatory requirements and explore alternative testing methods to maintain its market position and investor confidence.
In response to the FDA's decision, Charles River Laboratories has stated that it is actively exploring alternative testing methods and technologies. The company is investing in research and development to find viable alternatives to animal testing, which could help mitigate the impact of the regulatory change on its business. However, the transition to new testing methods will require significant investment and time, and the company's ability to adapt will be crucial in determining its future success. Investors will be closely watching Charles River Laboratories' progress in this area, as the company's ability to navigate this regulatory shift will have a significant impact on its stock performance and long-term viability.
